Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancerJennifer A. Byrne, Anna DeFazio, Rosemary L. Balleine et al.|International Journal of Cancer|2005Cited by 99
MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcomeJennifer A. Byrne, Philippa M. O’Brien, Jayne Hardy et al.|BMC Cancer|2010Cited by 64
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugsPei Y. Liu, Tao Liu, Bing Liu et al.|Oncotarget|2016Cited by 21
A Pathway to Precision Medicine for Aboriginal Australians: A Study ProtocolYeu-Yao Cheng, Kylie Gwynne, Jack Nunn et al.|Methods and Protocols|2021Cited by 21
A pathway to precision medicine for Aboriginal Australians: a study protocolYeu-Yao Cheng, Kylie Gwynne, Jack Nunn et al.|Molecular Genetics and Metabolism|2021Cited by 2